Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Exemestane is a prescription steroidal aromatase inhibitor used in postmenopausal women with selected hormone-sensitive breast cancers. It is indicated after two to three years of tamoxifen for estrogen receptor-positive early breast cancer and for advanced breast cancer that progresses after tamoxifen. Tablets contain 25 mg.
read more about exemestane ...Aromatase converts androgens into estrogens in peripheral tissues. Exemestane binds irreversibly to aromatase and inactivates the enzyme, which lowers circulating estrogen concentrations in postmenopausal women. Reduced estrogen signaling can slow growth of estrogen-dependent breast cancer cells.
Exemestane is used in postmenopausal women with estrogen receptor-positive early breast cancer who switch from tamoxifen after two to three years to complete five consecutive years of adjuvant hormonal therapy. It also treats advanced breast cancer in postmenopausal women whose disease progresses after tamoxifen.
The recommended dose is one 25 mg tablet once daily after a meal. Treatment duration depends on the breast cancer indication and prior therapy. Estrogen-containing medicines are avoided during exemestane treatment since they can interfere with its pharmacologic action.
Exemestane can reduce bone mineral density and increase fracture risk. Vitamin D status is assessed before aromatase inhibitor treatment, and vitamin D deficiency is treated when present. Other concerns include fetal harm and laboratory abnormalities. Exemestane is not indicated for breast cancer treatment in premenopausal women.
Exemestane treats selected early and advanced breast cancers in postmenopausal women.
The recommended dose is 25 mg once daily after a meal.
Yes. Bone mineral density can decrease during treatment, which raises osteoporosis and fracture concerns.
No. Estrogen-containing medicines can interfere with the pharmacologic action of exemestane.
DailyMed - AROMASIN (exemestane) tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3. Date Accessed September 30, 2026.
Exemestane. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548926/. Date Accessed September 30, 2026.
Exemestane. MedlinePlus. https://medlineplus.gov/druginfo/meds/a607006.html. Date Accessed September 30, 2026.
Exemestane. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/exemestane. Date Accessed September 30, 2026.
Exemestane. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Exemestane. Date Accessed September 30, 2026.